Immunic Inc (NASDAQ:IMUX) shared encouraging results from their phase 2 CALDOSE-1 trial of vidofludimus calcium (IMU-838) during an oral presentation at the United European Gastroenterology Week 2023. The trial showcased statistically significant efficacy of vidofludimus calcium compared to a placebo, reinforcing its promising safety and tolerability profile for potential use in ulcerative colitis (UC) and other inflammatory bowel disease applications.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com